Please select the eligibility criteria that correspond to the clinical trial below.
Title: Cilostazol Stroke Prevention Study for Antiplatelet Combination
Brief Summary: To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in high-risk patients for stroke


Options:
A: Inclusion Criteria:

-Clinical diagnosis of ischaemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Symptoms must be distinguishable from an episode of generalised ischaemia (i.e. syncope), seizure, or migraine disorder.

Main inclusion criteria:

* Patients at risk of stroke who have had transient ischaemia of the brain or completed ischaemic stroke due to thrombosis
* Symptoms of ischaemic attack began less than 24 hours prior to study medication start, are to be present for at least 30 minutes and have not significantly improved before start of treatment
* Patients are eligible for platelet inhibiting treatment
* National Institute of Health Stroke Scale (NIHSS) between 5 and 20 (at pre-screening and screening)
* Actual Modified Rankin Scale (mRS) (at baseline) is worse than retrospective mRS (before stroke)
* A contraindication for stroke lysis is given
* Patients are able to give (at least oral) informed consent and to swallow either medication

Exclusion Criteria:

* Hypersensitivity to any of the components of the product or salicylates.
* Patients with active gastric or duodenal ulcers or with bleeding disorders.
* Pregnancy during the third trimester.
* Lysis therapy.
* A platelet inhibiting therapy with Acetylsalicylic Acid (ASA) doses of more than 100 mg per day, or with clopidogrel of any dose has been planned or started.
* Time of onset of stroke symptoms is unknown (when a stroke happened during night-/sleeping time, bedtime is assumed as time of onset)
B: Inclusion Criteria:

* Patients is on oral anticoagulation therapy and this will be continued throughout the period of 1 year-and deployment of at least 1 coronary stent (bare metal stent (BMS) or drug eluting stent (DES)). -age of more than 18 years

Exclusion Criteria:

* cardiogenic shock,
* contra-indication for aspirin or clopidogrel
* allergy to aspirin or clopidogrel,
* documented peptic ulcer disease within the previous six months,
* pregnancy and
* previous intracerebral haemorrhage or
* significant thrombocytopenia (platelet count \< 50x10 9/L).
* major bleeding according to timi criteria within the past 12 months
* age \> 80 years
C: Inclusion Criteria:

* Ischemic stroke diagnosed within 48 hours from symptom onset;
* Cerebral ischemic lesion observed on diffusion-weighted magnetic resonance imaging (DWI MRI);
* Relevant atherothrombotic lesions on magnetic resonance angiography (MRA) or computed tomography angiography (CTA);
* Study drug administration within 48 hours from symptom onset;
* mRS score is 0-2 before the stroke.

Exclusion Criteria:

* Evidences of other relevant brain lesions such as Intracerebral hemorrhage (ICH) or brain tumor;
* Suspicious of stroke due to small-vessel occlusion;
* Stroke due to cardioembolism;
* Clinical necessity of conventional angiography or intervention before the end of study;
* Past history of ICH;
* Bleeding diathesis or coagulopathy;
* Chronic anemia (Hb\<8.0) or thrombocytopenia (PLT\<100K);
* Chronic liver disease (AST\> 100 or ALT\>100);
* Any other clinically relevant serious disease, including renal failure ( creatinine clearance\<30mL/min);
* Allergy to Aspirin or clopidogrel;
* Subjected to intervention or surgical treatments within 3 months;
* Thrombolysis performed with rt-PA or UK after the stroke;
* Participation in another clinical study within the previous 30 days;
* Suspicious of poor drug compliance and requirements of the protocol;
* Females who are pregnant, breast-feeding, or childbearing potential and not using medically acceptable and effective contraception.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
D: Inclusion Criteria:

* Patients with a diagnosis of noncardioembolic IS that developed between 8 and 180 days before the start of the protocol treatment
* Patients with a responsible lesion identified by MRI
* Patients aged 20 to 85 years old when providing informed consent
* Patients taking clopidogrel or aspirin alone as antiplatelet therapy when providing informed consent
* Patients meeting at least one of the following criteria a-c:

  1. at least 50% stenosis of a major intracranial artery (to the level of A2, M2, or P2)
  2. at least 50% stenosis of an extracranial artery (the common carotid artery，internal carotid artery，vertebral artery，brachiocephalic artery，or subclavian artery)
  3. Two or more of the following risk factors

     * Aged 65 years or more
     * Diabetes mellitus
     * Hypertension
     * Peripheral arterial disease
     * Chronic kidney disease
     * History of IS (excluding the index IS for this study)
     * History of ischemic heart disease
     * Smoking (only current smokers)
* Patients considered to be able to visit the study site for ambulatory care throughout the observation period
* Patients who provided written informed consent

Exclusion Criteria:

* Patients with emboligenic heart disease
* Patients taking any anticoagulant agents
* Patients who cannot undergo MRI examination for reasons such as claustrophobia and implanted pacemaker
* Patients scheduled to undergo any surgery, such as percutaneous angioplasty, stent placement, and bypass grafting, during the study period
* Patients with a drug-eluting coronary stent implanted within one year
* Patients with a history of symptomatic non-traumatic intracranial hemorrhage, any other hemorrhagic disease (eg, active peptic ulcer), bleeding predisposition, or blood clotting disorders
* Patients with a history of hypersensitivity to cilostazol
* Patients with congestive heart failure or uncontrolled angina pectoris
* Patients with thrombocytopenia (platelet count ≦ 100,000/mm3)
* Patients with severe liver or renal dysfunction
* Women who are pregnant, breast-feeding, or of child-bearing potential
* Patients with a malignant tumor requiring treatment
* Patients who are taking aspirin, and meet any of the following criteria:

  * History of hypersensitivity to aspirin or salicylic acid analogues
  * Current peptic ulcer
  * Aspirin-induced asthma or its history
* Patients who are taking clopidogrel, and meet the following criterion:

  ・History of hypersensitivity to clopidogrel
* Patients who are participating in any other clinical studies
* Patients considered by the investigator/subinvestigator to be unsuitable for participating in this study

Answer: D